Back
Company

HerelleX recognized at Santander X Global Awards, MWC 2026

Our CEO, Agustín Pablo Seijo, shares the vision behind FluoTB, the low-cost tuberculosis diagnostic tool we are developing.

Retrato de Agustín Seijo
Agustín SeijoCEO
Grupo de emprendedores celebrando con sus premios en el escenario de los Santander X Global Awards, MWC Barcelona 2026.

The recognition

HerelleX was recognized at the Santander X Global Awards, held during MWC Barcelona 2026.

Agustín Pablo Seijo, CEO of HerelleX, with the Santander X Global Awards trophy at MWC Barcelona 2026.
Agustín Pablo Seijo, CEO of HerelleX, with the Santander X Global Awards trophy at MWC Barcelona 2026.

About FluoTB

We are developing FluoTB, a low-cost diagnostic tool based on engineered mycobacteriophages. Its goal is to make TB detection faster and more accessible, especially in low-resource and high-burden regions.

An incredible group of entrepreneurs from around the world at the Santander X Global Awards.
An incredible group of entrepreneurs from around the world at the Santander X Global Awards.

This recognition reinforces what drives HerelleX: turning cutting-edge research into scalable solutions with global health impact.

Thank you to Santander X for this opportunity and for supporting innovation with purpose.

See all news

Get involved

Bring FluoTB to where it's needed.

The potential market is ~200,000 tests a year in Argentina and over 30 million a year across high-incidence countries — a global TB-diagnostics market projected to grow from USD 2.28B in 2024 to USD 3.18B by 2030. If accessible diagnosis is your mission too, let's talk.

Simplified view

One sample. One test, adjusted to routine lab workflows.

A respiratory sample is processed with standard lab methods, incubated with our reagents, then fixed for safe fluorescence reading — even up to 10 days later.

01.

Decontamination

Competing flora is cleared.

02.

Infect and express

Sample meets phage reagents.

03.

Fixation

Fixed — safe to handle and store.